Akero Therapeutics

company

About

Akero Therapeutics is a biotechnology company focused on reversing the NASH epidemic by restoring the body’s metabolism to a balanced state.

  • 11 - 50

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$100M
Industries
Biotechnology,Life Science,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Akero Therapeutics is committed to providing meaningful treatment options for people with serious metabolic diseases like non-alcoholic steatohepatitis (NASH), a disease marked by inflammation in the liver and liver cell damage resulting in fibrosis, cirrhosis, liver failure, and death. The company is developing pioneering medicines designed to restore metabolic balance and halt NASH progression.

Akero's lead clinical program, AKR-001, is a long-acting Fc fusion modified FGF21 protein and potential best-in-class treatment for NASH. The AKR-001 builds upon two decades of work on FGF21 biology. It is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$235M
Akero Therapeutics has raised a total of $235M in funding over 2 rounds. Their latest funding was raised on Jun 16, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 16, 2022 Post-IPO Debt $100M 1 Hercules Capital Detail
Dec 12, 2018 Series B $70M 1 Detail
Jun 25, 2018 Series A $65M 1 Versant Ventures Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Akero Therapeutics has made 1 investments. Their most recent investment was on Mar 17, 2021, when SEON raised €10M.
Date Company Name
Round Money Raised Industry Lead Investor
Mar 17, 2021 SEON
Series A €10M Fraud Detection

Investors

Number of Lead Investors
Number of Investors
2
2
Akero Therapeutics is funded by 2 investors. Hercules Capital and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt
Versant Ventures Series B